Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gleave

Showing results (641-650 of 839) with videos related to

Pageof 84
Sort By:
Scientific Reports|September 15, 2017
Semaphorin 3 C drives epithelial-to-mesenchymal transition, invasiveness, and stem-like characteristics in prostate cellsKevin J Tam, Daniel H F Hui, Wilson W Lee, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Communications Biology|January 18, 2024
DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2Roosa Kaarijärvi, Heidi Kaljunen, Lucia Nappi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2026
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancerMartin Smoragiewicz, Alice Bernard-Tessier, Mark Linch, et al.
Bioorganic & Medicinal Chemistry Letters|June 29, 2010
Structure-activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X(7) receptorPaul J Beswick, Andy Billinton, Laura J Chambers, et al.
JAMA Oncology|May 6, 2016
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerAlexander W Wyatt, Arun A Azad, Stanislav V Volik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2017
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation TherapyHimisha Beltran, Alexander W Wyatt, Edmund C Chedgy, et al.
Oncotarget|December 30, 2014
Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancerDong Lin, Xin Dong, Kendric Wang, et al.
Journal of the National Cancer Institute|September 7, 2023
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trialTakayuki Sumiyoshi, Xiaofei Wang, Evan W Warner, et al.
Neoplasia (New York, N.Y.)|October 27, 2021
CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activationZheng Wang, Mohit Hulsurkar, Lijuan Zhuo, et al.
Pageof 84

Showing results (641-650 of 839) with videos related to

Sort By:
Pageof 84
Scientific Reports|September 15, 2017
Semaphorin 3 C drives epithelial-to-mesenchymal transition, invasiveness, and stem-like characteristics in prostate cellsKevin J Tam, Daniel H F Hui, Wilson W Lee, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Communications Biology|January 18, 2024
DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2Roosa Kaarijärvi, Heidi Kaljunen, Lucia Nappi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2026
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancerMartin Smoragiewicz, Alice Bernard-Tessier, Mark Linch, et al.
Bioorganic & Medicinal Chemistry Letters|June 29, 2010
Structure-activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X(7) receptorPaul J Beswick, Andy Billinton, Laura J Chambers, et al.
JAMA Oncology|May 6, 2016
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerAlexander W Wyatt, Arun A Azad, Stanislav V Volik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2017
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation TherapyHimisha Beltran, Alexander W Wyatt, Edmund C Chedgy, et al.
Oncotarget|December 30, 2014
Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancerDong Lin, Xin Dong, Kendric Wang, et al.
Journal of the National Cancer Institute|September 7, 2023
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trialTakayuki Sumiyoshi, Xiaofei Wang, Evan W Warner, et al.
Neoplasia (New York, N.Y.)|October 27, 2021
CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activationZheng Wang, Mohit Hulsurkar, Lijuan Zhuo, et al.
Pageof 84